Deltarasin is primarily used in biochemical and pharmaceutical research for its ability to selectively inhibit the interaction between PDEδ and prenylated proteins, particularly KRAS. This makes it a valuable tool in studying cancer cell signaling pathways, especially in tumors driven by KRAS mutations, which are common in pancreatic, lung, and colorectal cancers. By disrupting the localization of KRAS to the cell membrane, Deltarasin impairs oncogenic signaling and reduces cancer cell proliferation. It is often employed in cell-based assays and preclinical studies to evaluate the therapeutic potential of targeting protein trafficking in cancer. Its use helps researchers understand the role of spatial organization in cellular signaling and supports the development of novel anticancer agents.